Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COTRIVAP
2023-505108-52-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ventilator-associated pneumonia (VAP) and Pneumonia due to Enterobacteriaceae comparing Cotrimoxazole de-escalation with Standard-of-care antibiotics (2 arms). Primary endpoint: Vital status at day 28. Started Jul 2023; status: completed.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
ventilator-associated pneumonia (VAP)Pneumonia due to Enterobacteriaceae
Beyond the preview
Go deeper on 2023-505108-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505108-52-00.